NCT04562337View on ClinicalTrials.gov

SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
DRUG

SHR1316

Anti-PD-L1 antibody

DRUG

Carboplatin

Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

DRUG

Etoposide

Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

RADIATION

Radiation therapy

Thoracic radiation therapy ,TRT

DRUG

Cisplatin

Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Trial Locations (1)

Unknown

Shandong Cancer Hospital and Institute, Jinan

All Listed Sponsors
lead

Shandong Cancer Hospital and Institute

OTHER